Hospitalization and Continuity of Care in Anti-MDA5 Dermatomyositis

JAMA Dermatol. 2024 Jun 1;160(6):674-676. doi: 10.1001/jamadermatol.2024.0403.
No abstract available

Plain language summary

This cohort study describes the clinical features, patient characteristics, and treatment of anti-melanoma differentiation–associated gene 5 (MDA5) dermatomyositis.

MeSH terms

  • Adult
  • Autoantibodies / blood
  • Autoantibodies / immunology
  • Continuity of Patient Care* / organization & administration
  • Dermatomyositis* / drug therapy
  • Dermatomyositis* / immunology
  • Dermatomyositis* / therapy
  • Female
  • Hospitalization* / statistics & numerical data
  • Humans
  • Interferon-Induced Helicase, IFIH1* / immunology
  • Male
  • Middle Aged

Substances

  • Interferon-Induced Helicase, IFIH1
  • IFIH1 protein, human
  • Autoantibodies